Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announced today that it has established two subsidiary companies to accelerate the expansion of its commercial operations. Roslin Cell Therapies will carry forward its process development and manufacture of cell therapies for clinical trial. Roslin Cell Sciences will focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.
11 January 2016